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Prostaglandin E2Elevated levels of homocysteine produce detrimental effects in humans but its role in pretermbirth is not known.
Here we used a mouse model of hyperhomocysteinemia to examine the relevance of homocysteine to preterm
birth. The mouse carries a heterozygous deletion of cystathionine β-synthase (Cbs+/−). Gestational period was
monitored in wild type and Cbs+/− female mice. Mouse uterine and placental tissues, human primary tropho-
blast cells, and humanmyometrial and placental cell lineswere used to determine the inﬂuence of homocysteine
on expression of speciﬁc genes in vitro. The activity of BKCa channel in the myometrial cell line was monitored
using the patch-clamp technique. We found that hyperhomocysteinemia had detrimental effects on pregnancy
and induced preterm birth in mice. Homocysteine increased the expression of oxytocin receptor and Cox-2 as
well as PGE2 production in uterus and placenta, and initiated premature uterine contraction. A Cox-2 inhibitor
reversed these effects. Gpr109a, a receptor for niacin, induced Cox-2 in uterus. Homocysteine upregulated
GPR109A and suppressed BKCa channel activity in human myometrial cells. Deletion of Gpr109a in Cbs
+/−
mice reversed premature birth. We conclude that hyperhomocysteinemia causes preterm birth in mice through
upregulation of the Gpr109a/Cox-2/PGE2 axis and that pharmacological blockade of Gpr109amay have potential
in prevention of preterm birth.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Developmental maturity in human fetuses is completed between
34 and 37 weeks of gestation. Prematurely born babies lack this pro-
cess, which increases the risk of perinatal mortality andmorbidity [1].
Though multiple factors are believed to be responsible, the exact
mechanisms involved in preterm birth are poorly understood [2].
Recent epidemiological studies have suggested a potential role for in-
creased maternal plasma homocysteine levels in premature birth [3].
Homocysteine is an intermediate in methionine metabolism. It is
either remethylated to methionine by a folate/vitamin B12-dependent
enzyme (methionine synthase) or converted to cysteine by a vitamin
B6-dependent trans-sulfuration pathway with cystathionine as an
intermediate. Deﬁciency in folate, B12 or B6, can result in accumula-
tion of homocysteine. Elevated levels of homocysteine are also seen
in patients with mutations in N5, N10-methylenetetrahydrofolate+1 706 721 6608.
+1 706 721 9947.
apat@gru.edu (V. Ganapathy).
rights reserved.reductase (MTHFR) and cystathionine β-synthase (CBS) [4,5].
MTHFR generates N5-methyltetrahydrofolate, the coenzyme for me-
thionine synthase, while CBS is an enzyme in the trans-sulfuration
pathway. Elevated levels of homocysteine in circulation are causally
related to increased risk of coronary, cerebral, and peripheral arterial
diseases [5,6]. It is also a risk factor for preeclampsia, spontaneous
abortion and placental abruption [7,8].
Cbs knockout mouse has been generated as an animal model of
hyperhomocysteinemia to investigate the consequences of elevated
levels of homocysteine [9]. The circulating levels of homocysteine are
204 ± 65 μM in homozygous mice (Cbs−/−), 14 ± 3 μM in heterozy-
gousmice (Cbs+/−), and 6 ± 1 μM inwild typemice [9].When the het-
erozygotes are bred, the ratio of wild type mice to heterozygousmice is
close to the expected ratio based on theMendelian inheritance, and the
Cbs+/− mice have a lifespan comparable to that of wild type mice [9].
However, the number of homozygous mice is lower than expected,
and the Cbs−/− mice that are born have markedly shortened lifespan,
indicating that elevated levels of homocysteine not only have detrimen-
tal effects on pregnancy outcome but also on postnatal development
and growth [9]. Here we report an important, hitherto unrecognized,
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gous mice with signiﬁcantly elevated levels of homocysteine in circula-
tion always delivered pups prematurely, thus unraveling a causative
role of hyperhomocysteinemia in preterm birth. Mechanistic studies
show that preterm birth associated with elevated levels of homocyste-
ine is due to premature uterine contraction caused by the upregulation
of Cox-2 and oxytocin receptor, increased production of PGE2, and sup-
pression of BKCa channel activity. The niacin receptor Gpr109a appears
to mediate these effects of hyperhomocysteinemia because deletion of
Gpr109a in Cbs+/−mice reverses the preterm birth.
2. Materials and methods
2.1. Generation of Cbs+/−and Cbs+/−/Gpr109a −/− mice and timed
pregnancy
All animal procedures were reviewed and approved by the Institu-
tional Animal Care and Use Committee (IACUC) at the Georgia Health
Sciences University. Generation of Cbs−/− mice has been described
previously [9]. We obtained a breeding pair of Cbs+/− mice (C57Bl/6
background) from Jackson Laboratories (Bar Harbor, ME, U. S. A.) for
our studies. The mice were maintained in clear plastic cages with
12-h alternating light/dark cycles. Mice were fed a rodent diet
(7004 Teklad S-2335 Mouse Breeder Sterilizable Diet, Harlan Labora-
tories, Indianapolis, IN, U. S. A.). Wild type and Cbs+/− mice were set
up for mating at the end of the day, and females were examined on
the morning of the following day for vaginal plug. If the plug was
observed, the pregnancy was timed as 0.5 d of gestation, and the
littering day was recorded for each mouse. The pups were genotyped,
and the number of wild type, heterozygous, and homozygous pups in
each litter was recorded. For collection of placenta and uterus, a lon-
gitudinal incision was made in the lower abdomen on 16th day of
gestation, the uterine tract was taken out and cleared of perivascular
tissue, and the fetus, placenta, and the adjoining uterine tissue were
separated with scissors.
Gpr109a−/− mice were obtained from Dr. Stefan Offermanns
(Max-Planck-Institute for Heart and Lung Research, Bad Nauheim,
Germany). Generation of these mice has been described previously
[10]. Female Cbs+/− mice were ﬁrst crossed with Gpr109a−/− males
to generate Cbs+/−/Gpr109a+/− mice. The males and females of
the Cbs+/−/Gpr109a+/− genotype were then crossed to generate
Cbs+/−/Gpr109a−/− mice. Genotyping was accomplished by polymer-
ase chain reaction using gene-speciﬁc primers. Cbs+/−/Gpr109a−/− fe-
male mice were mated with Cbs+/−/Gpr109a−/− males to examine
the inﬂuence of Gpr109a deletion on gestational period in Cbs+/− fe-
male mice. This experiment was repeated with 5 different females,
and the data are presented as means ± S. E. Statistical signiﬁcance
was ﬁrst determined by ANOVA and then by Student's ‘t’ test, and
p b 0.05 was considered signiﬁcant.
2.2. RT-qPCR
Placenta and uterine tissues were isolated from wild type, Cbs+/−,
and Cbs−/−mice; RNAwas extracted using TRIzol (Invitrogen, Carlsbad,
CA, U. S. A.). Real-time PCRwas performed using SYBRGreen ﬂuorescein
mix from ABgene (Absolute QPCR; Thermo Scientiﬁc, Surrey, UK) and a
real-time PCR detection system (I-Cycler; Bio-Rad, Hercules, CA,
U. S. A.). The same method was used to monitor the expression of
speciﬁc genes in vitro in mouse uterine and placental tissues,
human primary trophoblast cells, and the human placental (BeWo)
and uterine myometrial (ULTR) cell lines, which were treated with
or without homocysteine (500 μM; 72 h). The treatment was carried
out inside a tissue culture hood under sterile conditions. Uterine and
placental tissues were prepared from wild type pregnant mice on
16th day of gestation. The tissue fragments were ﬁrst washed thor-
oughly in sterilized phosphate-buffered saline to remove blood,and then treated with homocysteine. Primary trophoblast cells
were prepared from term human placentas as described previously
[11]. BeWo and ULTR cells were cultured to 80–90% conﬂuency and
then treated with homocysteine. Total RNA was prepared from
control and treated tissues/cells and used for RT-qPCR.
2.3. Western blot
Lysates from placental and uterine tissues were used for western
blot. Membranes were probed with commercially available antibodies,
followed by appropriate horseradish peroxidase-conjugated secondary
antibodies (BIO-RAD, Hercules, CA, U. S. A.).
2.4. Immunohistochemistry
This was done on frozen sections using speciﬁc antibodies. After
treatment with primary antibodies, tissue sections were incubated
with appropriate AlexaFluor 555-conjugated IgG secondary antibodies
(Invitrogen, Carlsbad, CA, U. S. A.). Hoechst was used as the nuclear
stain. Slides were viewed with an epiﬂuorescence microscope (Carl
Zeiss Meditec, Oberkochen, Germany).
2.5. Measurement of homocysteine in mouse tissues
HPLCwas used tomeasure the levels of homocysteine inmouse pla-
centas of different genotype.Wild typemicewere set up for breeding to
obtain placentas of wild type genotype. Heterozygous mice were used
for breeding to obtain Cbs−/− placentas. In both cases, pregnant females
were killed on 16th of gestation and placental tissues were collected
and genotyped. Tissues were homogenized in phosphate-buffered sa-
line. The HPLC instrument included a controller (LCNet II), a solvent
mixing module (MX-2080–31), an autosampler (AS-2055), and a ﬂuo-
rescence detector (FP-1520 (Jasco, Inc., Easton, MD, U. S. A.). Two
HPLC columns were used: Supelco C18 and Supelguard C18 (Ascentis,
Bellefonte, PA, U. S. A.). Homocysteine levels were measured by a ﬂuo-
rometric method using the ﬂuorescent probe 7-ﬂuorobenzofurazan-
4-sulfonic acid that tags thiol groups. The values were normalized to
the internal standard N-acetyl cysteine. Values were normalized to
protein content of the tissue samples. Protein in tissue lysates was de-
termined by Lowry's method. Three individual samples were prepared
for each test group and measurements were repeated in duplicate.
The same technique was used also for the determination of plasma
levels of homocysteine in wild type and Gpr109a−/− mice. Blood was
collected from the retroorbital sinus in the presence of heparin as an an-
ticoagulant, and plasma was isolated by centrifugation. Protein in plas-
ma was precipitated with trichloroacetic acid, and the supernatant was
used for estimation of homocysteine. Three mice were used for each
genotype.
2.6. Analysis of uterine muscle contraction
Isometric tension analysis was performed with a Radnoti digital
force transducer organ bath system (Model 159920) using mouse
uterine ring preparations as previously described [12]. Brieﬂy, on
16th day of gestation, uterine tissues from wild type and Cbs+/−
pregnant female mice were dissected and cleaned of excess fat and
connective tissue. Two to four 5-mm rings were obtained from each
uterine tissue and prepared for isometric contractile force recordings.
The uterine rings were then mounted on two triangular tissue
supports, with one support ﬁxed to stationary glass rod, and the
other attached to a force–displacement transducer. Isometric contrac-
tions or relaxations were recorded in a computer using PowerChart
software from AD Instruments (Colorado Springs, CO, U. S. A.). The
tissue-bathing solution was the modiﬁed Krebs–Henseleit buffer:
122 mM NaCl, 4.7 mM KCl, 15.5 mM NaHCO3, 1.2 mM KH2PO4,
1.2 mM MgCl2, 1.8 mM CaCl2, 11.5 mM glucose, pH 7.2. The solution
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37 °C. Uterine ring preparations were equilibrated for 90 min under
a resting tension of 1 g, and fresh bath solution was added to the
tissue chamber every 30 min to prevent accumulation of metabolic
end products. After the initial equilibration, the tissue preparations
were exposed to maximally effective concentrations of oxytocin
(10 IU) to induce contractile response. After recording the response
for about 15 min, homocysteine (100 μM) was added to the bath
chamber. Again the response was recorded. To conﬁrm the effect
of homocysteine on oxytocin-induced contractions, the bath solution
was replaced with fresh Kreb's buffer, and the order of the addition of
oxytocin and homocysteine was reversed. Homocysteine (100 μM)
was added to the bath solution ﬁrst, the tissue response was
recorded, and then oxytocin (10 IU) was added and the tissue
response was recorded. The experiment was repeated with 3 wild
type uterine tissues and 3 Cbs+/− uterine tissues, and the data were
analyzed using PowerLab Chart5.1 Software. Results are given as
means ± S. E.
2.7. Patch clamp
Patch clamp experiments were performed using the human uter-
ine myometrial cell line ULTR. The bath solution consisted of
140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 20 mM HEPES,
and 20 mM glucose, pH 7.4. The patch pipettes with a resistance of
3 MΩ or less were made from capillaries of Corning glass 7052. To
measure potassium currents, the tips of the patch pipettes were ﬁlled
with a solution containing 90 mM KCH3SO3 (potassium methane-
sulfonate), 40 mM KCl, 5 mM MgCl2, and 20 mM HEPES, pH 7.4, to
approximate normal cellular [K+] and [Cl−]. The remainder of the pi-
pette was back-ﬁlled with a similar solution containing 200 mg/ml
amphotericin B. The experiments with cells were continued only if
the voltage drop across the series resistance was reduced to ≤ 5 mV
within 10–20 min after forming a gigaohm seal. To measure the rest-
ing membrane potential, the voltage reading was recorded while the
current-clamp mode was switched on. Voltage clamp and voltage
pulse generation were controlled with an Axopatch 200A patch
clamp ampliﬁer (Axon Instruments, Inc., Foster City, CA, U. S. A.)
and data were analyzed with pCLAMP 6.0.3 software (Axon Instru-
ments, Inc.), which is a comprehensive software package for acquisi-
tion and analysis of both whole-cell and single-channel currents.
Voltage-activated currents were ﬁltered at 2 kHz and digitized at
10 kHz, and capacitative and leakage currents were subtracted digi-
tally. All drugs were diluted with fresh bath solution and perfused
into the recording chamber.
2.8. PGE2 assay
To measure the levels of prostaglandin E2, we treated the uterine
myometrial cells (ULTR) and placental syncytiotrophoblast cells
(BeWo)with homocysteine chronically (cells exposed to homocysteine
for 5 passages) and collected the culture medium. PGE2 levels were
measured by ELISA using a commercially available kit (Cayman
Chemical Company, Ann Arbor, MI, U. S. A.). This assay was based
on the competition between PGE2 and a PGE2-acetylcholinesterase
(AChE) conjugate (PGE2 Tracer) for a ﬁxed amount of PGE2 monoclonal
antibody. When the concentration of PGE2 in tissue samples varies, the
amount of PGE2 Tracer that is able to bind to the PGE2 monoclonal anti-
body will be inversely proportional to the concentration of PGE2 in the
tissue sample. This antibody–PGE2 complex binds to goat polyclonal
anti-mouse IgG that had been coated in the well. The wells were
washed to remove any unbound reagents, and then Ellman's Reagent,
which contains the substrate to AChE, was added to the wells. The
product of this enzymatic reaction was monitored by measurement of
absorbance at 412 nm. The intensity of this color is proportional tothe amount of PGE2 Tracer bound to thewell, which is inversely propor-
tional to the amount of free PGE2 present in the tissue sample.
2.9. Microarray
Wild type × wild type matings and Cbs+/− × Cbs+/− matings were
set up, and placentas were collected on 16th day of gestation. The pla-
centas from the heterozygote mating were genotyped to identify
Cbs−/− placentas. Even though wild type placentas were obtained from
the heterozygote matings, these were not used for microarray because
these placentas were exposed to elevated levels of homocysteine during
pregnancy in Cbs+/− female mice. Therefore, the wild type placentas
used in microarray analysis were from wild type × wild type matings.
Three wild type placentas and three Cbs−/− placentas were used for iso-
lation of total RNA using the Trizol method. Double-stranded cDNA was
synthesized from 80 to 100 ng total RNA through a random-primed re-
verse transcription using a dNTPmix containing dUTP. After puriﬁcation,
the cDNA was fragmented by incubation with a mixture of UDG
(uracil-DNA glycosylase) and APE1 restriction endonucleases and
end-labeled via a terminal transferase reaction incorporating a
biotinylated dideoxynucleotide. The fragmented, biotinylated cDNA
(5.5 pg) was added to a hybridization cocktail, loaded on a Mouse
Gene 1.0 ST Gene Chip and hybridized for 18 h at 45 °C. Following
hybridization, the array was washed and stained according to the
Affymetrix protocols. The stained arrays were scanned at 532 nm using
an Affymetrix GeneChip Scanner 3000, generating CEL ﬁles for each
array.
Gene expression alterations were determined using PARTEK Ge-
nomics Suite. The data were then subjected to Principal Component
Analysis. A gene summarization was then performed on the data,
which estimates the intensity of individual genes by averaging the in-
tensities of all the probe sets comprising the gene. The summarization
is followed by an n-way analysis of variance (ANOVA) using a mixed
model and methods of moment to equate ANOVA mean sum of
squares to their expected values. The data was then analyzed using
a two sample t-test for signiﬁcance at p b 0.05 and a fold change cut
off of 2.
3. Results
3.1. Hyperhomocysteinemia causes premature delivery in mice
Heterozygote matings (Cbs+/− × Cbs+/−) used in the present study
yielded a total of 63 wild type mice (Cbs+/+), 115 heterozygous mice
(Cbs+/−), and 49 homozygous mice (Cbs−/−) with a corresponding
ratio of 1:1.8:0.8. The ratio of wild type and heterozygousmice in the lit-
ters was close to what was expected of Mendelian inheritance. The pro-
portion of Cbs−/− pups was however less than expected, suggestive of
signiﬁcant embryonic lethality of the Cbs−/− genotype. Cbs+/− mice
grew normal and there was no apparent phenotype associated with
this genotype except for the signiﬁcantly elevated homocysteine levels
in plasma. Cbs+/− females were fertile, but interestingly pregnant
Cbs+/−mice littered prematurely compared to wild type mice (Fig. 1A;
gestation period in wild type mice, 20.0 ± 0.2 days; gestation period
in Cbs+/−mice, 16.6 ± 0.1 days; p b 0.001).We also found that the pla-
cental weight and body weight of Cbs−/− fetuses were signiﬁcantly
lower compared towild type and Cbs+/− littermates (Fig. 1B, C). The pri-
mary site of Cbs expression is liver, but we found that Cbs was also
expressed in uterus and placenta (Fig. 1D, E). Homocysteine levels
were higher in Cbs−/− placentas (0.17 ± 0.02 pmol/μg protein) than
in wild type placentas (0.09 ± 0.01 pmol/μg protein; p b 0.01) (Fig. 1F).
3.2. Role of Cox-2 in premature delivery in Cbs+/− mice
We analyzed the differential gene expression in wild type and
Cbs−/− placentas by microarray (Supplemental Table 1). One of the
Fig. 1. Hyperhomocysteinemia causes premature delivery in mice. (A) Gestation period in wild type (WT) and Cbs+/− mice (Mean ± S. E., ***p b 0.001). (B) Fetal weight in wild
type (WT) and Cbs+/−mice on 16th day of pregnancy (Mean ± S. E., NS, not signiﬁcant; **p b 0.01; ***p b 0.001). (C) Placental weight in wild type (WT) and Cbs+/−mice on 16th
day of pregnancy (Mean ± S. E., NS, not signiﬁcant; **p b 0.01; ***p b 0.001). (D) RT-PCR and western blot analysis of cystathionine β-synthase (Cbs) expression in wild type (WT)
and Cbs−/− (KO) liver, placenta and uterus. (E) Immunoﬂuorescence analysis of liver and placenta for Cbs protein in wild type (WT) and Cbs−/− mice. (F) Homocysteine (Hcy)
levels in wild type (WT) and Cbs−/− placentas on 16th day of pregnancy (**p b 0.01).
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ﬁrmed its upregulation by RT-qPCR, western blot and immunohisto-
chemistry (Fig. 2A–C). The upregulation was also evident in Cbs+/−
uterus (similar data could not be obtained for Cbs−/− uterus because
Cbs−/− females do not survive long enough to reach the reproductive
age). RT-qPCR showed a ~11 fold increase in Cox-2 expression in
Cbs−/− placenta and ~5 fold increase in Cbs+/− uterus on 16th day
of gestation. This raised the possibility that the preterm birth ob-
served in Cbs+/− female mice may be due to homocysteine-induced
increase in PGE2 production through Cox-2. To conﬁrm that Cox-2
was responsible for the premature birth in Cbs+/− mice, we adminis-
tered Celecoxib, a selective Cox-2 inhibitor, by oral gavage to Cbs+/−
pregnant mice once a day on 15th and 16th day of gestation (25 mg/kg
bodyweight). This treatment increased the gestation period signiﬁcantly
(vehicle versus Celecoxib, p b 0.01) (Fig. 2D). In contrast, Cbs+/− preg-
nant mice treated with vehicle littered prematurely. We examined the
inﬂuence of homocysteine on PGE2 production in a human uterine
myometrial cell line (ULTR) and a human placental trophoblast cell
line (BeWo). Chronic treatment of these cells with homocysteine (cells
exposed to homocysteine for 5 passages) increased PGE2 secretion
(Fig. 2E; p b 0.01 for BeWo; p b 0.001 for ULTR). We also examined the
tissue levels of PGE2 in wild type placentas and in placentas of different
Cbs genotypes (Fig. 2F). The PGE2 levels were higher in Cbs−/− placentas
than inwild type or Cbs+/−placentas (p b 0.05).We also examinedPGE2
levels inwild type uterine tissue fromwild type femalesmatedwithwildtype males and in Cbs+/− uterine tissues attached to placentas of differ-
ent Cbs genotypes. The latter were obtained from Cbs+/− females mated
with Cbs+/− males. We found elevated levels of PGE2 in Cbs+/− uterus
compared to wild type uterus (p b 0.01) (Fig. 2F). Among the Cbs+/−
uterine tissues attached to placentas of different Cbs genetic back-
grounds, PGE2 levels were higher in tissues attached to Cbs−/−
placentas than in tissues attached to wild type or Cbs+/− placentas
(p b 0.05).3.3. Effect of homocysteine on uterine muscle contraction
We then monitored the contractile features of uterine muscle from
wild type and Cbs+/− pregnant mice. Oxytocin induced the contraction
of the uterine tissue from wild type as well as Cbs+/− mice; there was
a trend of increased contraction in Cbs+/− uterine tissue, but the differ-
encewas not statistically signiﬁcant (Fig. 3A, B). Homocysteine had a sig-
niﬁcant augmenting effect on oxytocin-induced contraction in wild type
uterus, but this effect was signiﬁcantly greater in Cbs+/− uterus
(p b 0.05). Homocysteine itself caused uterine contraction, but the effect
was much greater in Cbs+/− uterus than in wild type uterus (p b 0.01).
Even though the effects of oxytocin by itself on uterine contraction
were not different between wild type and Cbs+/− uterine muscle, in
the presence of homocysteine, oxytocin elicited a greater effect on uter-
ine contraction in Cbs+/− uterus than in wild type uterus (p b 0.05).
Fig. 2. Role of Cox-2 in premature delivery in Cbs+/−mice. (A) RT-qPCR analysis of Cox-2 mRNA in wild type (WT) placenta and uterus and in Cbs−/− placenta and Cbs+/− uterus on
day 16 of pregnancy (**p b 0.01; ***p b 0.001). (B) Western blot of Cox-2 in wild type (WT) placenta and uterus and in Cbs−/− placenta and Cbs+/− uterus on day 16 of pregnancy.
(C) Immunohistochemical analysis of Cox-2 in wild type placenta and uterus and in Cbs−/− placenta and Cbs+/− uterus on day 16 of pregnancy. (D) Signiﬁcant reversal of preterm
birth in Cbs+/−mice by Cox-2 inhibitor Celecoxib. The drug was administered at a dose of 25 mg/kg body weight by oral gavage once a day on day 15 and 16 of pregnancy (Mean ±
S. E., **p b 0.01). (E) PGE2 levels secreted by control and homocysteine (Hcy)-treated BeWo cells and ULTR cells (Hcy treatment: 0.5 mM, four passages; **p b 0.01; ***p b 0.001).
(F) PGE2 levels in placenta and uterus with different Cbs genetic backgrounds. Wild type (WT) placentas and uterine tissues were obtained on 16th day of gestation from matings
wild type females with wild type males. In a separate experiment, matings of heterozygous mice were set up, and on 16th day of gestation, placentas and the regions of the uterine
tissues attached to each of the placentas were separated. The placental tissues were genotyped. Mean ± S. E., * p b 0.05; **p b 0.01.
1153S.R. Sonne et al. / Biochimica et Biophysica Acta 1832 (2013) 1149–11583.4. Effect of homocysteine on BKCa channel expression and activity in the
uterine myometrial cell line ULTR
We examined the inﬂuence of homocysteine on expression of the
two subunits of the BKCa channel in the human uterine myometrial cell
line ULTR. This was prompted by published reports that BKCa channels
play a critical role in uterine contraction [13–16]. In cells that were cul-
tured in the presence of homocysteine for 5 passages, the α-subunit
was upregulated whereas the regulatory β-subunit was downregulated
(Fig. 3C). We then monitored the BKCa channel activity in these cells by
measuring large outward K+ currents using the whole-cell patch-
clamp technique. Resting membrane potential was signiﬁcantly less in
homocysteine-treated cells than in control cells (Fig. 3D; p b 0.05).
These ﬁndings were suggestive of depressed K+ channel function. We
then measured macroscopic currents generated by incremental 10 mV
depolarizing steps (from−60 to+60 mV).Whole-cell recordings dem-
onstrated a robust outward current whose kinetics suggested both a
rapid and a more long-lasting component (Fig. 3E, left panel). Interest-
ingly, both the peak and steady-state outward currents were reduced
dramatically in homocysteine-treated cells. In the presence of 1 mM
4-aminopyridine, an inhibitor of voltage-dependent K+ channels (Kv),
the fast activation component was abolished leaving a prominent,
slow-activating, non-inactivating outward current that was highly sensi-
tive to blockade by 1 mM tetraethyl ammonium, which at this concen-
tration exhibits selectivity for BKCa channels. These studies suggest that
homocysteine exerts a powerful inhibitory inﬂuence upon outward
potassium currents in uterinemyometrial cells, and that amajor compo-
nent of these currents is indeed due to activity of BKCa channels.3.5. Effect of homocysteine on the expression of oxytocin and progesterone
receptors
We also compared the expression of several other genes that are re-
lated to uterine activity between wild type and Cbs+/− uterine tissues
collected on 16th day of gestation. The expression of oxytocin receptor
was increased several-fold in Cbs+/− uterus compared to wild type
uterus (Fig. 4A, B). In heterozygote matings (Cbs+/− × Cbs+/−), the ex-
pression level varied in different regions of the uterine horn depending
on the genotype of the placenta that was attached to the given region.
The expression was the lowest in the region attached to wild type pla-
centa and highest in the region attached to Cbs−/− placenta. In contrast
to oxytocin receptor, the expression of progesterone receptor was less
in Cbs+/− uterus than in wild type uterus (Fig. 4C).
3.6. Effect of homocysteine on the expression of Cox-2 and the receptors
for oxytocin and prostaglandins in placenta and uterus
Even though we have demonstrated that exogenous homocysteine
induces Cox-2 expression in the human uterine myometrial cell line
ULTR and the human placental trophoblast cell line BeWo, concerns
may arise with these ﬁndings because of the transformed nature of
these cell lines. Therefore, to validate our ﬁndings further, we used
organ cultures of mouse pregnant uterine tissue and placental tissue.
On gestation day 16, wild type pregnant mice were euthanized and
uterine and placental tissues were collected. The tissues were chopped
into ﬁne pieces, washed thoroughly to remove blood, and then used for
organ cultures under sterile conditions with or without homocysteine
Fig. 3. Effects of homocysteine (Hcy) on uterinemuscle preparations from 16-day pregnantwild type and Cbs+/−mice. (A)Muscle contraction tracings with uterine rings fromwild type
and Cbs+/−mice (oxytocin, 10 IU; Hcy, 100 μM). (B) Contractions from 3 different animals were quantiﬁed (Mean ± S. E., NS, not signiﬁcant; *p b 0.05; **p b 0.01). (C) Western blot of
theα- and β-subunits of the BKCa channel in control and Hcy-treated (0.5 mM; 4 passages) ULTR cells. (D) Restingmembrane potential in control and Hcy-treated (0.5 mM; 4 passages)
ULTR cells (Mean ± S. E.; *p b 0.05). (E)Whole-cell patch-clamp recordings of outward currents in control and Hcy-treated (0.5 mM; 4 passages) ULTR cells in the absence and presence
of 1 mM 4-aminopyridine (4-AP), an inhibitor of voltage-dependent (Kv) channels, with or without 1 mM tetraethylammonium (TEA), an inhibitor of BKCa channel.
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analysis of gene expression. Similar experiments were also carried out
with primary placental trophoblast cells prepared from normal termFig. 4. Expression of oxytocin receptor and progesterone receptor in Cbs+/−mouse uterus.
16 of pregnancy. Wild type (WT) uterine tissues were obtained on 16th day of gestation from
of heterozygous mice were set up, and on 16th day of gestation, placentas and the regions
tissues were genotyped. The expression of oxytocin receptor was then analyzed using RNA is
genotype. The genotype of the uterine tissue in all these regions is Cbs+/−. (B) Immunohistoc
(C) RT-qPCR showing downregulation of progesterone receptor (Pgr) in Cbs+/− uterus on dhuman placentas. We found that homocysteine treatment increased
the expression of Cox-2 as well as that of the oxytocin receptor in all
three preparations (Fig. 5). The prostaglandin receptor EP3 was also(A) RT-qPCR showing upregulation of oxytocin receptor (Oxtr) in Cbs+/− uterus on day
matings of wild type females with wild type males. In a separate experiment, matings
of the uterine tissues attached to each of the placentas were separated. The placental
olated from the regions of the uterine tissue that were attached to placentas of different
hemical analysis of Oxtr in wild type and Cbs+/− uterine tissues on day 16 of pregnancy.
ay 16 of pregnancy.
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cells, but this was not seen with organ cultures of mouse uterine and
placental tissues.
3.7. Reversal of preterm birth in Cbs+/− mice by deletion of Gpr109a
Based on the published reports that GPR109A, a G-protein-coupled
receptor for niacin, induces COX-2 and increases production of prosta-
glandins in some cell types [17,18], we wanted to know if
homocysteine-induced preterm birth in mice was mediated through
this receptor. We ﬁrst examined if there are differences in circulating
levels of homocysteine between wild type mice and Gpr109a−/−mice.
The plasma concentration of homocysteine in wild type mice was
4.8 ± 0.1 μM, and the corresponding value in Gpr109a−/− mice was
3.2 ± 0.3 μM. This difference was signiﬁcant (p b 0.05). We then gen-
erated Cbs+/− mice on Gpr109a+/+ and Gpr109a−/− backgrounds and
compared the gestational period between the two mouse lines. While
Cbs+/− females on Gpr109a+/+ background littered prematurely,
Cbs+/− females on Gpr109a−/− background had normal gestational pe-
riod (Fig. 6A). This reversal of preterm birth in Cbs+/− females upon de-
letion of Gpr109a was accompanied by reversal of Cox-2 expression in
placenta and uterus (Fig. 6B). We also found that the expression of
Gpr109a was increased in both Cbs−/− placenta and Cbs+/− uterus in
response to hyperhomocysteinemia (Fig. 6C). The inﬂuence of homo-
cysteine on GPR109A expression was also seen in BeWo and ULTR
cells (Fig. 6D). Placenta and uterus from wild type mice express
Gpr109a constitutively, and the expression is increased in mice with
hyperhomocysteinemia (Fig. 6E).
4. Discussion
The ﬁndings of the present study can be summarized as follows. Ele-
vated levels of homocyteine have detrimental effects in mice during
pregnancy, which include signiﬁcant embryonic lethality, decreased pla-
cental weight, decreased birth weight, and preterm delivery. Homocys-
teine is known for its profound effects on vasculature [19,20] and has
been implicated in the pathogenesis of preeclampsia [7,8]. However,
there have been no reports in the literature on the role of this amino
acid in premature birth. Our present studies show for the ﬁrst time
that elevated levels of homocysteine in mice induce preterm birth. The
underlying molecular mechanism involves homocysteine-induced
upregulation of Cox-2 and consequent generation of the uterotonic mol-
ecule prostaglandin E2 as well as upregulation of the oxytocin receptor.
Cox-2 induction and increased production of PGE2 are observed in the
uterine and placental tissues obtained from the hyperhomocysteinemic
pregnant mice. Exogenous homocysteine induces contraction of uterine
muscle by itself and also potentiates oxytocin-mediated contraction in
vitro. Administration of Celecoxib, a pharmacological blocker of Cox-2,
to hyperhomocysteinemic pregnantmice provides signiﬁcant protection
against preterm birth. The ability of homocysteine to upregulate Cox-2
and oxytocin receptor is seen not only in human uterine myometrial
and placental cell lines but also in organ cultures of mouse uterine and
placental tissues and in primary cultures of human placental tropho-
blasts. Therefore, it appears that Cox-2 and its product PGE2 in both uter-
us and placenta are likely to contribute to the premature uterine
contraction seen in hyperhomocysteinemic female mice. Even though
our studies have unequivocally demonstrated the induction of Cox-2Fig. 5. Induction of Cox-2 and oxytocin receptor by homocysteine in organ cultures of
mouse uterine and placental tissues and in human primary placental trophoblast cells.
(A & B) Uterine and placental tissues were collected from wild type pregnant mice on
day 16 of gestation. The tissues were cut into small pieces and washed thoroughly with
sterile phosphate-buffered saline to remove blood. The tissue fragments were then cul-
tured under sterile conditions for 72 h in the presence or absence of homocysteine
(500 μM). Total RNA was then isolated and used for RT-qPCR. (C) Similar experiments
were carried with primary trophoblast cells isolated from normal human term placentas.
Fig. 6. Reversal of preterm birth in Cbs+/−mice by deletion of Gpr109a. (A) Gestational period in wild type mice and in Cbs+/− mice on Gpr109a+/+ and Gpr109a−/− backgrounds
(Mean ± S. E.; ***p b 0.001). (B) RT-qPCR of Cox-2 mRNA levels in placentas and uteri fromwild type and Cbs+/−mice on Gpr109a+/+ and Gpr109a−/− backgrounds on 16th day of
pregnancy (Mean ± S. E.). (C) RT-qPCR of Gpr109a mRNA levels in wild type and Cbs−/− placentas and in wild type and Cbs+/− uterus; (D) RT-qPCR of GPR109A mRNA levels in
control and Hcy-treated (0.5 mM; 4 passages) BeWo and ULTR cells. (E) Immunohistochemical analysis of Gpr109a expression in wild type placenta and uterus, Cbs−/− placenta
and Cbs+/− uterus.
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with the process remain to be investigated.
Normal pregnancy is associated with increased oxidative stress, and
this is aggravated even further in pre-eclampsia [21]. Homocysteine is
known to cause oxidative stress [5,6], and elevated levels of homocyste-
ine constitute a risk factor for pre-eclampsia [7,8]. Since Cbs is an enzyme
in the trans-sulfuration pathway that is essential for endogenous synthe-
sis of cysteine, a limiting amino acid for glutathione biosynthesis, it is
likely that disruption of the Cbs gene results in decreased glutathione
and consequently increased oxidative stress. There are reports implicat-
ing oxidative stress in the induction of COX-2 [22]. Therefore, if elevated
levels of homocysteine induce oxidative stress, this could serve as a sig-
nal in the homocysteine-induced upregulation of Cox-2.It is not known at presentwhether pretermbirth observed in Cbs+/−
mice is evident in othermouse models of hyperhomocysteinemia. Such
models have been described in the literature [23]. For example, nutri-
tional manipulations (e.g., methionine loading via modiﬁed diet, limit-
ing the dietary content of the vitamins folic acid, B12, or B6) can
elevate the circulating levels of homocysteine in mice. However, there
are limitations to the use of dietary models of hyperhomocysteinemia
because dietary manipulations not only cause an increase in homocys-
teine but also lead to alterations in other metabolites and biochemical
pathways. Therefore, even if any of these mouse models is associated
with preterm birth, it may be difﬁcult to ascertain unequivocally the
role of homocysteine as the factor responsible for this phenotype.
There are two other genetic models of hyperhomocysteinemia in
1157S.R. Sonne et al. / Biochimica et Biophysica Acta 1832 (2013) 1149–1158mice: Mthfr-deﬁcient mouse [24] and methionine synthase-deﬁcient
mouse [25]. Mthfr−/− mice have elevated levels of homocysteine and
suffer from decreased survival, and motor and gait abnormalities. Ho-
mozygous deletion of methionine synthase is embryonically lethal
whereas heterozygous deletion of the gene results in no signiﬁcant
changes in circulating levels of homocysteine. Therefore, Mthfr−/−
mice may provide an additional animal model suitable to investigate
the relevance of hyperhomocysteinemia to preterm birth. Apparently,
the gestational period in this mouse model has not yet been examined
because we could not ﬁnd any information in the literature on this
issue. This was also the case with Cbs+/− mouse; this mouse model
was ﬁrst reported almost 20 years ago [9], but the gestational age was
not investigated until the present study. Therefore, it would be of inter-
est to investigate the gestational period inMthfr−/−mice in the future
to complement the present ﬁndings in Cbs+/−mice.
Homocysteine contains a reactive thiol group and is known to cova-
lently modify proteins via a process called homocysteinylation [26]
This process also interferes with collagen crosslinking by breaking
down disulﬁde bonds through formation of mixed disulﬁdes with cyste-
ine residues in collagen [26]. In addition, collagen synthesis and
cross-linking are also affected by mercaptopropionaldehyde, a metabo-
lite of homocysteine [27]. The effects on vasculature and collagen are be-
lieved to be the primary reasons for the clinical symptoms associated
with hyperhomocysteinemia, which include thrombosis, osteoporosis,
and dislocation of lens [28]. Here we provide evidence for the ﬁrst time
that uterus is also a prime target for homocysteine. Elevated levels of ho-
mocysteine have profound effects on this tissue. The effects include
changes in the expression of various genes that are closely associated
with uterine function. Exposure of uterus to homocysteine increases
the expression of oxytocin receptor but decreases the expression of
progesterone receptor, thus simultaneously enhancing the contractile
response of the tissue to oxytocin and decreasing the ability of progester-
one to relax the tissue. In addition, induction of Cox-2 with consequent
generation of prostaglandins also facilitates homocysteine-induced
uterine contraction. The enhanced contractile response of uterine tissues
from pregnant hyperhomocysteinemic mice to oxytocin provides
supporting evidence for homocysteine-induced promotion of uterine
contraction. Even though the present studies focused on the Cox-2/
PGE2 pathway as the underlying mechanism for the premature
contraction associated with hyperhomocysteinemia, other pathways
may also be potentially relevant. Homocysteine has been shown to
increase the production of pro-inﬂammatory cytokines [29,30] and
metalloproteinases [31,32], both of which have been implicated in pro-
motion of uterine contraction and cervical ripening.
Even though there are signiﬁcant differences between mice and
humans in terms of biological processes associated with parturition,
the present ﬁndings implicating elevated levels of homocysteine as a
risk factor for preterm birth in mice are likely to be relevant to humans.
There is evidence from epidemiological studies that folic acid deﬁciency
is linked to preterm delivery in humans [33–38]. One of the biochemical
hallmarks of folic acid deﬁciency is hyperhomocysteinemia, thus impli-
cating homocysteine as a potential causative factor in preterm birth
observed in humans with folic acid deﬁciency. Elevated levels of homo-
cysteine have also been shown to be a pathogenic factor in preeclampsia,
a condition associated with preterm delivery [7,8]. These observations
suggest that plasma levels of homocysteine during pregnancy may
have potential as a biomarker to predict the risk of premature birth.
Various nutritional and genetic factors contribute to the plasma levels
of homocysteine in humans. Since homocysteine is either converted to
methionine by the folate/B12-dependent enzyme methionine synthase
or converted to cysteine by vitamin B6-dependent trans-sulfuration
pathway, deﬁciency in folate, B12 or B6 can result in accumulation of ho-
mocysteine. Elevated levels of homocysteine are also seen in patients
with mutations in methionine synthase and cystathionine β-synthase.
However, the frequency of mutations in these two enzymes is rare in
the general population. Another enzyme whose activity is related tocirculating levels of homocysteine is N5, N10-methylenetetrahydrofolate
reductase (MTHFR). This enzyme is obligatory in the synthesis of
N5-methyltetrahydrofolate necessary for the remethylation of homocys-
teine by methionine synthase. Mutations in MTHFR are quite prevalent
in general population [39,40], and these mutations result in an increase
in circulating levels of homocysteine. The most frequent genetic alter-
ations in MTHFR are Ala222Val (C→T mutation) and Glu429Ala (A→C
mutation). The variations in plasma levels of homocysteine in the gener-
al population are primarily due to MTHFR mutations coupled with die-
tary folic acid intake status. It would be interesting and important to
determine if there is any signiﬁcant correlation between circulating
levels of homocysteine during pregnancy and the length of gestation in
humans.
The involvement of the niacin receptor Gpr109a in homocysteine ef-
fects on uterus is an unexpected surprise ﬁnding. When we initiated
this work, it was not even known that this receptor is expressed in
the utero-placental unit. Present studies show that it is not only
expressed abundantly in placenta and uterus but also plays a role in
homocysteine-induced facilitation of uterine contraction. Exposure of
both tissues to homocysteine enhances the expression of the receptor
even further. The obligatory nature of the involvement of the receptor
in preterm birth associated with hyperhomocysteinemia is supported
by the ﬁndings that deletion of this receptor in hyperhomocysteinemic
mice prevents preterm birth.
The ﬁndings of the present studies have immense clinical relevance
considering the fact that preterm birth causes a signiﬁcant increase in
morbidity and mortality in babies. These studies demonstrate that ele-
vated levels of homocysteine in blood in pregnant women could serve
as a biomarker to predict the risk of premature delivery. Strategies to re-
duce the levels of homocysteine, such as nutritional supplementation
with folic acid, B12, and B6, could be used as a prophylaxis to decrease
the risk of premature delivery. MTHFR mutations decrease the afﬁnity
of the enzyme for N5, N10-methylenetetrahydrofolate; therefore, folic
acid supplementation would be able to correct the defect in the enzyme
activity by increasing the concentrations of the coenzyme available for
the mutant enzyme. Pharmacologically, 17α-hydroxyprogesterone re-
mains as the only drug used at present in pregnancy for prevention of
preterm birth [41,42]. Our present studies open up a new avenue for de-
velopment of novel drugs for prevention of preterm birth by focusing on
antagonists that interfere with GPR109A signaling in the utero-placental
unit.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.04.006.
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